Year: 2022
Type: review
Abstract: Most screening programs to identify individuals at risk for type 1 diabetes have targeted relatives of people living with the disease to improve yield and feasibility. However, ∼90% of those who develop type 1 diabetes do not have a family history. Recent successes in disease-modifying therapies to impact the course of early-stage disease have ignited the consideration of the need for and feasibility of population screening to identify those at increased risk. Existing population screening programs rely on genetic or autoantibody screening, and these have yielded significant information about disease progression and approaches for timing for screening in clinical practice. At the March 2021 Type 1 Diabetes TrialNet Steering Committee meeting, a session was held in which ongoing efforts for screening in the general population were discussed. This report reviews the background of these efforts and the details of those programs. Additionally, we present hurdles that need to be addressed for successful implementation of population screening and provide initial recommendations for individuals with positive screens so that standardized guidelines for monitoring and follow-up can be established.
Source: Diabetes
DOI: 10.2337/dbi20-0054
Authors: Emily K. Sims, Rachel E.J. Besser, Colin Dayan, Cristy Geno Rasmussen, Carla Greenbaum, Kurt J. Griffin, William Hagopian, Mikael Knip, Anna E. Long, Frank Martin, Chantal Mathieu, Marian Rewers, Andrea K. Steck, John M. Wentworth, Stephen S. Rich, Olga Kordonouri, Anette-Gabriele Ziegler, Kevan C. Herold, for the NIDDK Type 1 Diabetes TrialNet Study Group
Institutions: Indiana University School of Medicine, Centre for Human Genetics, John Radcliffe Hospital, National Institute for Health and Care Research, University of Oxford, Cardiff University, University of Colorado Anschutz, Benaroya Research Institute, Sanford Health, University of Helsinki, Helsinki University Hospital, Tampere University Hospital, University of Bristol, Breakthrough T1D, Universitair Ziekenhuis Leuven, KU Leuven, The Royal Melbourne Hospital, Walter and Eliza Hall Institute of Medical Research, University of Virginia, Kinderkrankenhaus auf der Bult, Helmholtz Munich, Institute of Diabetes Research, Technical University of Munich, Yale University
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W4220917002